Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | WDR91 | A4D1P6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406790 | 0.91 | CHRNB2 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL18013342 | 0.90 | CHRNB2 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL5412162 | 0.84 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL25852559 | 0.81 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL17796709 | 0.81 | CCR6 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL23707244 | 0.81 | CCR6 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL15205522 | 0.81 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL26951386 | 0.78 | CHRNB2 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL17843209 | 0.77 | CHRNB2 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4AR | |
| SCHEMBL25855696 | 0.77 | CCR6 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | PETERS DAN | 2007-07-12 | — | — | US | claimed |
| EP-1357121-A1 | Azaring-ether deritatives and their use as nicotinic ach receptor modulators | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | claimed |
| EP-1034174-B1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2003-08-13 | — | — | EP | claimed |
| EP-1034174-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2000-09-13 | — | — | EP | claimed |
| WO-1999024422-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-05-20 | — | — | WO | claimed |
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | PETERS DAN | 2007-07-12 | — | — | US | disclosed |
| US-7202237-B2 | Pyridylether derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20040242558-A1 | Pyridylether derivatives, their preparation and use | NEUROSEARCH A/S | 2004-12-02 | — | — | US | disclosed |
| US-6756386-B1 | SUCH AS 1-METHYL-3-OXY-(5-CHLORO-3-PYRIDYL)-PIPERIDINE; CHOLINERGIC SYSTEM OF CENTRAL NERVOUS SYSTEM; PAIN, INFLAMMATION | NEUROSEARCH A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| EP-1357121-A1 | Azaring-ether deritatives and their use as nicotinic ach receptor modulators | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | disclosed |
| EP-1034174-B1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2003-08-13 | — | — | EP | disclosed |
| EP-1034174-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999024422-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | CHRNA4, CHRNA5, CHRM3 | CHRNB4 15/4885CHRNA3 5/4885CHRNB2 18/4885 |
| US-20040242558-A1 | Pyridylether derivatives, their preparation and use | CHRNA4, CHRNA5, CHRM3 | CHRNB4 15/4885CHRNA3 5/4885CHRNB2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.